In the present study, all the participants that were evaluated for MIP-1A gene expression received a second dose of COVID-19 vaccine before SARS-CoV-2 infection, but blood samples for the study were taken at least 6 months after COVID-19 diagnosis. This evidence concerns the gene CCL3 and COVID-19.